Veru Inc. reported its financial results for the three months ended December 31, 2025. The company recorded a net loss of USD 5.33 million for the period, representing a reduction of 40% compared to the same quarter in the previous year. Net loss per basic and diluted common share and pre-funded warrants was USD 0.26. Research and development expenses decreased by 77% to USD 1.3 million, while general and administrative expenses declined by 21% to USD 4.1 million. Operating loss from continuing operations was USD 5.4 million, down 47%. Cash, cash equivalents and restricted cash totaled USD 33 million as of December 31, 2025. The company had 20,311,190 basic and diluted weighted average common shares and pre-funded warrants outstanding during the period. Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The company’s development pipeline includes two late-stage new chemical entities: enobosarm and sabizabulin. Enobosarm is being developed as an oral selective androgen receptor modulator (SARM) aimed at making weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, which is expected to improve body composition and physical function. Sabizabulin is also in late-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9652222) on February 11, 2026, and is solely responsible for the information contained therein.